SOUTH SAN FRANCISCO, Calif. , Dec. 29, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health , today announced that a second leading independent proxy advisory firm, Glass, Lewis & Co.
Glass Lewis Recommendation Emphasizes Strong Strategic Rationale and Thorough Process ISS Reiterates Recommendation Following Public Commentary Recommendations Reiterate that Value Maximizing Transaction Is in the Best Interests of Stockholders; Board Urges Stockholders to Vote "FOR" the
Continues to Recommend Stockholders Vote "FOR" Pending Merger ISS has Dismissed Madryn's Misleading Claims and Reaffirms that Stockholders Vote "FOR" the Merger BOULDER, Colo., Dec. 29, 2023 /PRNewswire/ -- SomaLogic, Inc. (Nasdaq: SLGC ) ("the Company"), a leader in proteomics technology, today
SOUTH SAN FRANCISCO, Calif. , Dec. 22, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health - today announced that leading independent proxy advisory firm Institutional Shareholder Services (“ISS”)
Company Urges Stockholders to Vote “FOR” Value Maximizing Transaction at Upcoming Special Meeting BOULDER, Colo., Dec. 22, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that Institutional Shareholder Services (“ISS”) has recommended that SomaLogic
Combination Builds Scale and Accelerates Path to Profitability, Unlocking Significant Potential Value for SomaLogic Stockholders Madryn’s Concerns are Not Based on Facts, and Madryn Selectively Ignores Risks in a Standalone Strategy and Potential Benefits of the Merger Urges Stockholders to Vote
SOUTH SAN FRANCISCO, Calif. and BOULDER, Colo. , Dec. 04, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – and SomaLogic, Inc. (Nasdaq: SLGC), a leader in data-driven proteomics technology, today
Year-to-date revenue growth, gross margin expansion and operating expense reduction are testament to continued execution against financial objectives Planned merger with SomaLogic activates strategic M&A thesis SOUTH SAN FRANCISCO, Calif. , Nov. 07, 2023 (GLOBE NEWSWIRE) -- BioTools Inc.
SOUTH SAN FRANCISCO, Calif. , Nov. 02, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that President and Chief Executive Officer Michael Egholm , PhD, will give a presentation
SOUTH SAN FRANCISCO, Calif. , Oct. 25, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that it will report third quarter 2023 financial results on Tuesday, November 7, 2023,
